Scancell Holdings plc (LON:SCLP - Get Free Report) shares crossed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of GBX 9.88 ($0.13) and traded as low as GBX 9.73 ($0.13). Scancell shares last traded at GBX 10.95 ($0.15), with a volume of 1,472,135 shares changing hands.
Scancell Trading Up 9.5%
The company has a market capitalization of £113.36 million, a PE ratio of -16.78 and a beta of 0.35. The company has a quick ratio of 13.01, a current ratio of 3.42 and a debt-to-equity ratio of -566.79. The stock's fifty day moving average price is GBX 9.77 and its two-hundred day moving average price is GBX 9.88.
Insider Buying and Selling at Scancell
In other news, insider Martin Diggle acquired 44,944 shares of the business's stock in a transaction dated Tuesday, May 20th. The shares were purchased at an average price of GBX 9 ($0.12) per share, with a total value of £4,044.96 ($5,472.08). 4.96% of the stock is currently owned by corporate insiders.
About Scancell
(
Get Free Report)
Scancell LSE: SCLP is a clinical stage immunotherapy biotech company developing treatments for significant unmet needs in cancer. We aim to translate our innovation and creativity into increased and durable responses in patients without compromising safety, addressing hard-to-treat cancers.
Scancell has developed a pipeline of ‘off-the-shelf' vaccines to induce immune responses and highly tumour specific monoclonal antibodies to redirect immune cells or drugs.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Scancell, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Scancell wasn't on the list.
While Scancell currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
